Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499126 | 0.86 | DRD2 (0.39) | THRBTHRAKDM4EP4HBNPSR1 | |
| SCHEMBL6492219 | 0.84 | DRD2 (0.36) | THRBTHRAKDM4EP4HBNPSR1 | |
| SCHEMBL7132256 | 0.83 | KDM4E (0.35) | THRBTHRAKDM4EP4HBNPSR1 | |
| SCHEMBL7132250 | 0.82 | KDM4E (0.35) | THRBTHRAKDM4EP4HBNPSR1 | |
| SCHEMBL6497406 | 0.81 | BRD4 (0.41) | DRD2MEN1KMT2AL3MBTL1 | |
| SCHEMBL6492750 | 0.79 | KDM4E (0.43) | KDM4ENPSR1MEN1GAAKMT2A | |
| SCHEMBL6489796 | 0.79 | MAPT (0.42) | MEN1GAAKMT2AL3MBTL1 | |
| SCHEMBL7070085 | 0.78 | MAPT (0.36) | KDM4EP4HBNPSR1MEN1GAA | |
| SCHEMBL7064560 | 0.76 | HRH3 (0.39) | KDM4EGAAL3MBTL1 | |
| SCHEMBL6301182 | 0.76 | KMT2A (0.47) | KDM4EMEN1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | THRB 2919/4885THRA 3559/4885KDM4E 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.